Research programme: cannabis-based therapeutics - NEMUS Bioscience

Drug Profile

Research programme: cannabis-based therapeutics - NEMUS Bioscience

Alternative Names: Cannabidiol derivatives - NEMUS; Cannabionoid therapeutics - NEMUS; CBD derivatives - NEMUS; NB 1111; NB 2111; NB 2221; NB 23R1; NB 31R1; NB 51R1

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator NEMUS Bioscience; University of Mississippi
  • Class Cannabinoids; Non-opioid analgesics
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chemotherapy-induced nausea and vomiting; Muscle spasticity; Open-angle glaucoma; Pain; Peripheral nervous system diseases
  • Research Anxiety disorders; Epilepsy; Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 01 Dec 2016 Preclinical trials in Chemotherapy induced nausea and vomiting in USA before December 2016 (unspecified route)
  • 16 Jun 2016 Pharmacodynamics data from a preclinical trial in Open angle glaucoma released by Nemus Bioscience
  • 10 Jun 2016 NEMUS signed a letter of intent to license biosynthetic technology to manufacture its proprietary cannabinoid molecules from Teewinot Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top